BACKGROUND: Detectable levels of cardiac troponins are common in individuals with chronic kidney disease (CKD), even in the absence of symptomatic cardiovascular disease. Abnormal cardiac troponin values are associated with coronary artery disease and left ventricular hypertrophy (LVH) and predict poor clinical outcomes. Elevated levels of fibroblast growth factor 23 (FGF-23) contribute to LVH in CKD. We investigated the association of FGF-23 and hs-cTnI (high-sensitivity cardiac troponin I) and hs-cTnT (high-sensitivity cardiac troponin T) levels in CKD and examined the role of LVH in this association. STUDY DESIGN: Cross-sectional observational study. SETTING & PARTICIPANTS: 153 stable outpatients with non-dialysis-dependent CKD. PREDICTOR: The primary predictor was FGF-23 level. OUTCOMES: hs-cTnI, hs-cTnT. MEASUREMENTS: FGF-23, hs-cTnI, hs-cTnT; left ventricular mass index (LVMI) assessed by echocardiography; coronary artery calcification (CAC) measured by computed tomography. LVMI and CAC were evaluated as potential mediators of the effect of FGF-23 on hs-cTnI/T. RESULTS: Mean age was 64 ± 12 (SD) years, mean estimated glomerular filtration rate was 34 ± 11 mL/min/1.73 m(2), median FGF-23 level was 120 (25th-75th percentile, 79-223) reference unit (RU)/mL, median hs-cTnI level was 6.5 (25th-75th percentile, 3.5-14.5) pg/mL, and median hs-cTnT level was 16.8 (25th-75th percentile, 11.1-33.9) pg/mL. cTnI and cTnT concentrations were higher than the 99th percentile of a healthy population in 42% and 61% of patients, respectively. In unadjusted and multivariable-adjusted analyses, hs-cTnI/T levels were associated significantly with FGF-23 levels. Adjusting for LVMI, but not CAC, weakened the association of FGF-23 and hs-cTnI/T levels. LIMITATIONS: Vitamin D levels were not measured. The prevalence of coronary artery disease may have been underestimated because it was ascertained by self-report. CONCLUSIONS: Minimally elevated cTnI and cTnT levels, detectable by high-sensitivity assays, are associated with elevated FGF-23 levels in stable outpatients with CKD. FGF-23-associated LVH may contribute to detectable hs-cTnI/T levels observed in non-dialysis-dependent patients with CKD.
BACKGROUND: Detectable levels of cardiac troponins are common in individuals with chronic kidney disease (CKD), even in the absence of symptomatic cardiovascular disease. Abnormal cardiac troponin values are associated with coronary artery disease and left ventricular hypertrophy (LVH) and predict poor clinical outcomes. Elevated levels of fibroblast growth factor 23 (FGF-23) contribute to LVH in CKD. We investigated the association of FGF-23 and hs-cTnI (high-sensitivity cardiac troponin I) and hs-cTnT (high-sensitivity cardiac troponin T) levels in CKD and examined the role of LVH in this association. STUDY DESIGN: Cross-sectional observational study. SETTING & PARTICIPANTS: 153 stable outpatients with non-dialysis-dependent CKD. PREDICTOR: The primary predictor was FGF-23 level. OUTCOMES: hs-cTnI, hs-cTnT. MEASUREMENTS: FGF-23, hs-cTnI, hs-cTnT; left ventricular mass index (LVMI) assessed by echocardiography; coronary artery calcification (CAC) measured by computed tomography. LVMI and CAC were evaluated as potential mediators of the effect of FGF-23 on hs-cTnI/T. RESULTS: Mean age was 64 ± 12 (SD) years, mean estimated glomerular filtration rate was 34 ± 11 mL/min/1.73 m(2), median FGF-23 level was 120 (25th-75th percentile, 79-223) reference unit (RU)/mL, median hs-cTnI level was 6.5 (25th-75th percentile, 3.5-14.5) pg/mL, and median hs-cTnT level was 16.8 (25th-75th percentile, 11.1-33.9) pg/mL. cTnI and cTnT concentrations were higher than the 99th percentile of a healthy population in 42% and 61% of patients, respectively. In unadjusted and multivariable-adjusted analyses, hs-cTnI/T levels were associated significantly with FGF-23 levels. Adjusting for LVMI, but not CAC, weakened the association of FGF-23 and hs-cTnI/T levels. LIMITATIONS: Vitamin D levels were not measured. The prevalence of coronary artery disease may have been underestimated because it was ascertained by self-report. CONCLUSIONS: Minimally elevated cTnI and cTnT levels, detectable by high-sensitivity assays, are associated with elevated FGF-23 levels in stable outpatients with CKD. FGF-23-associated LVH may contribute to detectable hs-cTnI/T levels observed in non-dialysis-dependent patients with CKD.
Authors: Allan J Collins; Robert N Foley; Blanche Chavers; David Gilbertson; Charles Herzog; Kirsten Johansen; Bertram Kasiske; Nancy Kutner; Jiannong Liu; Wendy St Peter; Haifeng Guo; Sally Gustafson; Brooke Heubner; Kenneth Lamb; Shuling Li; Suying Li; Yi Peng; Yang Qiu; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Bryn Thompson; Changchun Wang; Eric Weinhandl; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frank Daniels; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa Journal: Am J Kidney Dis Date: 2012-01 Impact factor: 8.860
Authors: Sherri-Ann M Burnett-Bowie; Benjamin Z Leder; Maria P Henao; Chantel M Baldwin; Douglas L Hayden; Joel S Finkelstein Journal: Clin J Am Soc Nephrol Date: 2012-02-02 Impact factor: 8.237
Authors: Martin L Ford; Edward R Smith; Laurie A Tomlinson; Prabal K Chatterjee; Chakravarthi Rajkumar; Stephen G Holt Journal: Nephrol Dial Transplant Date: 2011-07-12 Impact factor: 5.992
Authors: Tamara Isakova; Huiliang Xie; Allison Barchi-Chung; Gabriela Vargas; Nicole Sowden; Jessica Houston; Patricia Wahl; Andrew Lundquist; Michael Epstein; Kelsey Smith; Gabriel Contreras; Luis Ortega; Oliver Lenz; Patricia Briones; Phyllis Egbert; T Alp Ikizler; Harald Jueppner; Myles Wolf Journal: Clin J Am Soc Nephrol Date: 2011-09-08 Impact factor: 8.237
Authors: M C Iliou; C Fumeron; M O Benoit; P Tuppin; C L Courvoisier; V M Calonge; N Moatti; C Buisson; C Jacquot Journal: Nephrol Dial Transplant Date: 2001-07 Impact factor: 5.992
Authors: J Dierkes; U Domröse; S Westphal; A Ambrosch; H P Bosselmann; K H Neumann; C Luley Journal: Circulation Date: 2000-10-17 Impact factor: 29.690
Authors: Rachel M Holden; David Beseau; Sarah L Booth; Michael A Adams; Jocelyn S Garland; Ross A Morton; Christine P Collier; Robert N Foley Journal: Hemodial Int Date: 2012-01 Impact factor: 1.812
Authors: Faraz S Ahmad; Xuan Cai; Katherine Kunkel; Ana C Ricardo; James P Lash; Dominic S Raj; Jiang He; Amanda H Anderson; Matthew J Budoff; Julie A Wright Nunes; Jason Roy; Jackson T Wright; Alan S Go; Martin G St John Sutton; John W Kusek; Tamara Isakova; Myles Wolf; Martin G Keane Journal: Am J Hypertens Date: 2017-08-01 Impact factor: 2.689
Authors: Julia J Scialla; Huiliang Xie; Mahboob Rahman; Amanda Hyre Anderson; Tamara Isakova; Akinlolu Ojo; Xiaoming Zhang; Lisa Nessel; Takayuki Hamano; Juan E Grunwald; Dominic S Raj; Wei Yang; Jiang He; James P Lash; Alan S Go; John W Kusek; Harold Feldman; Myles Wolf Journal: J Am Soc Nephrol Date: 2013-10-24 Impact factor: 10.121
Authors: Tamara Isakova; Jessica Houston; Laura Santacruz; Eva Schiavenato; Gabriel Somarriba; William G Harmon; Steven E Lipshultz; Tracie L Miller; Paolo G Rusconi Journal: Pediatr Nephrol Date: 2013-06-06 Impact factor: 3.714
Authors: Attila Kovács; Mihály Tapolyai; Csilla Celeng; Edit Gara; Mária Faludi; Klára Berta; Astrid Apor; Andrea Nagy; András Tislér; Béla Merkely Journal: Int J Cardiovasc Imaging Date: 2014-07-08 Impact factor: 2.357
Authors: Mark M Mitsnefes; Aisha Betoko; Michael F Schneider; Isidro B Salusky; Myles Selig Wolf; Harald Jüppner; Bradley A Warady; Susan L Furth; Anthony A Portale Journal: Clin J Am Soc Nephrol Date: 2017-10-12 Impact factor: 8.237
Authors: Seong Min Lee; Alex H Carlson; Melda Onal; Nancy A Benkusky; Mark B Meyer; J Wesley Pike Journal: Endocrinology Date: 2019-12-01 Impact factor: 4.736